

BC Cancer Extravasation Hazard Table

VESICANT	NONVESICANT	
	IRRITANT	NONE
amsacrine busulfan carmustine DACTINomycin DAUNOrubicin DOXOrubicin epirubicin IDArubicin melphalan mitomycin streptozocin treosulfan vinBLASline vinCRISline vindesine vinorelbine	arsenic trioxide azaCITIDine bendamustine bortezomib CISplatin dacarbazine DOCEtaxel DOXOrubicin pegylated liposomal etoposide fluorouracil gemcitabine ifosfamide mesna (undiluted) mitoXANTRONE *oxaliplatin *PACLitaxel *PACLitaxel-nab teniposide trastuzumab emtansine (KADCYLA®)	aldesleukin alemtuzumab asparaginase avelumab BCG bevacizumab bleomycin blinatumomab brentuximab vedotin buserelin cabazitaxel CARBOplatin carfilzomib cetuximab cladribine clodronate cyclophosphamide cytarabine daratumumab degarelix dexrazoxane dinutuximab durvalumab eriBULin fludarabine goserelin inotuzumab ozogamicin interferon ipilimumab irinotecan leucovorin leuprolide mesna (diluted) methotrexate octreotide oBINutuzumab nivolumab pamidronate PANitumumab pembrolizumab pemetrexed PERTuzumab plerixafor pralatrexate ramucirumab raltitrexed riTUXimab romiDEPsin temsirolimus testosterone thiotepa topotecan trastuzumab zoledronic acid

*Follow guidelines and treat like a vesicant.

For definitions of different categories of extravasation hazard and the details on management of extravasation, see BC Cancer Systemic Therapy Policy III-20 [Prevention and Management of Extravasation of Chemotherapy](#).